Reducing the Risks of Hyperkalemia in the Treatment of Heart Failure and Chronic Kidney Disease: What It Means for Management Teams

Did you know that up to 47% of patients taking renin-angiotensin-aldosterone system inhibitors see their therapy discontinued after developing mild or moderate-to-severe hyperkalemia? Credit available for this activity expires: 5/31/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/992401?ecd=bdc_podcast_libsyn_mscpedu